GlassScriptPhysician profile
Robert A Lester
NPI 1982643177
$9,703.33
in general payments reported to CMS, 2019-2025
51 companies · $1,965 in 2025
The $1,965 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,394 · 2020: $719 · 2021: $649 · 2022: $1,427 · 2023: $1,540 · 2024: $2,009 · 2025: $1,965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,514.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,108.27 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,073.30 | 2019-2025 | |
| Abbvie INC. | $988.77 | 2019-2025 | |
| Lilly USA, LLC | $687.25 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $626.45 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $622.23 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $417.67 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $388.43 | 2019-2023 | Jardiance |
| Abbott Laboratories | $375.88 | 2022-2025 | Proclaim, Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $305.60 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Takeda Pharmaceuticals U.S.A., INC. | $280.91 | 2019-2022 | |
| Exact Sciences Corporation | $260.64 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $205.57 | 2023-2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $198.66 | 2019-2025 | Qelbree |
| Bayer Healthcare Pharmaceuticals INC. | $188.77 | 2021-2025 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.